Artiva Biotherapeutics Full Year 2024 Earnings: Misses Expectations

Artiva Biotherapeutics (NASDAQ:ARTV) Full Year 2024 Results

Key Financial Results

• Net loss: US$65.4m (loss widened by 128% from FY 2023).
• US$5.81 loss per share.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

ARTV Products In Clinical Trials

• Phase I: 7.
• Phase II: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Artiva Biotherapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 6.1%. Earnings per share (EPS) also missed analyst estimates by 9.3%.

In the last 12 months, the only revenue segment was Pharmaceuticals contributing US$251.0k. The largest operating expense was Research & Development (R&D) costs, amounting to US$50.3m (75% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$1.91m. Explore how ARTV's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 10% from a week ago.

Risk Analysis

Be aware that Artiva Biotherapeutics is showing 5 warning signs in our investment analysis and 2 of those are significant...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.